CDSCO Advisory on GLP-1 Receptor Agonists for Obesity and Metabolic Disorders (2026)

CDSCO Advisory on GLP-1 Receptor Agonists for Obesity and Metabolic Disorders (2026)

The information provided in this article on the CDSCO advisory, GLP-1 receptor agonists, obesity treatment, and pharmaceutical regulations in India is intended for general informational and educational purposes only. It is based on publicly available regulatory updates and should not be considered as legal, medical, or professional advice.

While efforts have been made to ensure accuracy and relevance in line with the Drugs and Cosmetics Act, 1940, CDSCO guidelines, and pharmaceutical compliance standards, readers are advised to consult qualified professionals or regulatory experts before making any decisions based on this content.

This article does not promote or advertise any prescription medicines, including GLP-1 receptor agonists, and strictly adheres to applicable norms related to drug promotion, regulatory compliance, and ethical pharmaceutical marketing practices in India.

The Central Drugs Standard Control Organization (CDSCO), under the Directorate General of Health Services, has issued an important advisory dated 10^th March, 2026 regarding the promotion and communication of prescription medicines, particularly GLP-1 receptor agonists used for obesity and metabolic disorders. The advisory highlights regulatory requirements under the Drugs and Cosmetics Act, 1940 and the Drugs Rules, 1945 to ensure responsible promotion of pharmaceutical products.

According to the advisory, manufacturers and importers of drugs must ensure that the manufacture, sale, distribution, labeling, and promotion of medicines strictly comply with approved indications and marketing authorization conditions. CDSCO observed that some pharmaceutical companies may be engaging in direct or indirect promotional activities, including disease awareness campaigns and digital marketing, related to GLP-1 receptor agonists and other prescription-only drugs.

The regulator clarified that prescription medicines must only be prescribed by registered medical practitioners and should not be promoted directly to the general public. Any promotional communication that exaggerates therapeutic benefits, claims guaranteed weight loss, or encourages unnecessary pharmacological therapy may be treated as misleading advertising which will attract regulatory action under the provisions of the Drugs Rules and principles associated with Schedule J.

The advisory further emphasized that obesity is a chronic metabolic condition that requires comprehensive management, including lifestyle modification, diet control, physical activity, and behavioral interventions. Pharmaceutical treatment should not be presented as a substitute for these essential public health measures.

Any promotional activity, including the so called “awareness campaigns”, that functions as a surrogate advertisement for prescription-only drugs shall be viewed seriously and may be treated as misleading marketing practices. 

Accordingly, all manufacturers, importers, and marketing authorization holders are advised to adhere to:

Ensure strict compliance with the Act and Rules

Prescribing Information/Patient Information Leaflet/Product Information Sheet (PIS) shall properly display the details of authorised persons and their office code. It shall include the contact details along with the complaint reference mechanism for addressing consumer queries and reporting.

Advertisement including surrogate advertisement shall be strictly prohibited. This includes and extends to any direct and indirect promotional activities in all forms.

All manufacturers and marketing Authorization Holders shall strictly comply with all applicable ethical and regulatory norms, to ensure that vulnerable populations are not exploited.

To reduce the residual risk, the firms are required to submit comprehensive Risk Management Plan (RMP) which will ensure continued safety monitoring and implementation of risk minimization measures.

Click here to know more and access the official guidance document

Note:
Cases related to Pharmaceuticals are highly technical and knowledge-driven. If you're searching for a drugs and cosmetics lawyer in India, a pharmaceutical lawyer, Mace Corporate Associates is the perfect place. If you are searching for a DPCO Lawyer for overcharging cases or DPCO Compliance, Mace can assist you well. May it be a clinical trial Lawyer or a Medical device lawyer, Mace can be of great and perfect match for Pharmaceutical litigation. Mace has an accomplished track record for Not of Standard Quality Cases, Licensing Cases etc.